Telix Pharmaceuticals (TLX) Competitors $10.80 -0.06 (-0.55%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.79 -0.01 (-0.09%) As of 10/17/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLX vs. ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, and RVMDShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Telix Pharmaceuticals (NASDAQ:TLX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Does the media prefer TLX or ASND? In the previous week, Telix Pharmaceuticals had 12 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 29 mentions for Telix Pharmaceuticals and 17 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.72 beat Telix Pharmaceuticals' score of -0.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, TLX or ASND? Telix Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M7.07$32.93MN/AN/AAscendis Pharma A/S$393.54M33.00-$409.12M-$5.16-40.79 Do analysts recommend TLX or ASND? Telix Pharmaceuticals presently has a consensus price target of $21.00, suggesting a potential upside of 94.44%. Ascendis Pharma A/S has a consensus price target of $249.80, suggesting a potential upside of 18.67%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.94 Is TLX or ASND more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Ascendis Pharma A/S -54.94%N/A -24.31% SummaryTelix Pharmaceuticals beats Ascendis Pharma A/S on 6 of the 10 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.66B$3.44B$6.13B$10.55BDividend YieldN/A2.27%5.72%4.83%P/E RatioN/A23.3151.2627.06Price / Sales7.07487.09602.44132.30Price / Cash94.5845.2825.8230.35Price / Book9.6410.3812.246.58Net Income$32.93M-$52.81M$3.33B$276.84M7 Day Performance13.21%2.08%0.62%-0.72%1 Month Performance8.22%12.60%6.83%2.16%1 Year PerformanceN/A11.18%59.07%34.63% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix Pharmaceuticals3.7794 of 5 stars$10.80-0.6%$21.00+94.4%N/A$3.66B$516.72M0.00N/AASNDAscendis Pharma A/S2.8194 of 5 stars$208.43-0.5%$248.29+19.1%+62.0%$12.93B$393.54M-40.391,017Analyst ForecastRDYDr. Reddy's Laboratories3.0582 of 5 stars$14.36+0.1%$16.95+18.1%-9.4%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris3.0387 of 5 stars$9.86+1.2%$10.40+5.5%-13.5%$11.36B$14.74B-3.4032,000ROIVRoivant Sciences2.9491 of 5 stars$16.21+1.1%$19.94+23.0%+44.8%$10.95B$29.05M-23.16860Insider TradeBBIOBridgeBio Pharma4.4921 of 5 stars$55.96+0.8%$63.94+14.3%+111.1%$10.61B$221.90M-13.68400MRNAModerna4.2384 of 5 stars$26.74-0.3%$41.81+56.4%-51.9%$10.48B$3.24B-3.555,800Trending NewsOptions VolumeAnalyst RevisionGap DownQGENQIAGEN4.1454 of 5 stars$47.30+1.0%$49.40+4.4%+15.5%$10.41B$1.98B27.955,765Positive NewsELANElanco Animal Health2.5717 of 5 stars$20.04+1.4%$19.14-4.5%+65.2%$9.82B$4.44B23.309,000Gap UpVRNAVerona Pharma PLC American Depositary Share1.5394 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.4042 of 5 stars$48.75+1.1%$74.64+53.1%+7.3%$9.02B$11.58M-10.83250Analyst ForecastGap Up Related Companies and Tools Related Companies ASND Alternatives RDY Alternatives VTRS Alternatives ROIV Alternatives BBIO Alternatives MRNA Alternatives QGEN Alternatives ELAN Alternatives VRNA Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
